My small investment in Protalix is starting to show promise. Analysts says that its price will be 8$ after FDA approval (Current price 6$) and there is an 80% probability of approval before May. The significance of the FDA approval will be the validation of the plant-base cell expression system. PLX could represent an attractive acquisition to a firm seeking to become a player in generic biologics.
No comments:
Post a Comment